Natera’s Non-Invasive Prenatal Testing Technology Shows Unparalleled Specificity, Sensitivity in Clinical Data Presented at American Society of Human Genetics

Published: Nov 09, 2012

SAN CARLOS, Calif.--(BUSINESS WIRE)--Natera presented additional data from an ongoing clinical study of the company’s non-invasive prenatal screening test that demonstrates consistently high detection of chromosomal abnormalities from fetal cell-free DNA found in maternal blood. The data were presented in a poster presentation at the annual meeting of the American Society of Human Genetics in San Francisco on Thursday, November 8.

Back to news